LinkedIn

 آمار

تعداد نشریات20
تعداد شماره‌ها1,089
تعداد مقالات9,995
تعداد مشاهده مقاله26,236,592
تعداد دریافت فایل اصل مقاله7,247,243
Forouzani-Haghighi, Bahareh, Rezvani, Alireza, Vazin, Afsaneh. (1401). Immune Targeted Therapies for COVID-19 Infection: A Narrative Review. سامانه مدیریت نشریات علمی, 47(4), 291-299. doi: 10.30476/ijms.2021.91614.2277
Bahareh Forouzani-Haghighi; Alireza Rezvani; Afsaneh Vazin. "Immune Targeted Therapies for COVID-19 Infection: A Narrative Review". سامانه مدیریت نشریات علمی, 47, 4, 1401, 291-299. doi: 10.30476/ijms.2021.91614.2277
Forouzani-Haghighi, Bahareh, Rezvani, Alireza, Vazin, Afsaneh. (1401). 'Immune Targeted Therapies for COVID-19 Infection: A Narrative Review', سامانه مدیریت نشریات علمی, 47(4), pp. 291-299. doi: 10.30476/ijms.2021.91614.2277
Forouzani-Haghighi, Bahareh, Rezvani, Alireza, Vazin, Afsaneh. Immune Targeted Therapies for COVID-19 Infection: A Narrative Review. سامانه مدیریت نشریات علمی, 1401; 47(4): 291-299. doi: 10.30476/ijms.2021.91614.2277

Immune Targeted Therapies for COVID-19 Infection: A Narrative Review

Iranian Journal of Medical Sciences
مقاله 2، دوره 47، شماره 4، مهر 2022، صفحه 291-299    اصل مقاله (396.11 K)
نوع مقاله: Review Article
شناسه دیجیتال (DOI): 10.30476/ijms.2021.91614.2277
نویسندگان
Bahareh Forouzani-Haghighi1؛ Alireza Rezvani* 2، 3؛ Afsaneh Vazin1
1Department of Clinical Pharmacy, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran
2Department of Hematology and Medical Oncology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
3Hematology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
چکیده
In December 2019, the coronavirus disease-2019 (COVID-19) outbreak emerged in Wuhan, China. The World Health Organization officially declared it a pandemic on March 11, 2020. Reports indicated that the associated mortality of the infection is quite higher in the elderly, individuals with specific comorbidities (such as diabetes mellitus), and generally the ones with a compromised immune system. A cohort study in Wuhan, China, reported a dysregulated immune response in 452 patients with laboratory-confirmed COVID-19. As a result of this suppressed immune response, an increase in neutrophil to lymphocyte ratio, T lymphopenia, and a decrease in CD4+ T cells were all common laboratory findings, especially in severe cases.
On the other hand, there is substantial evidence of T cell exhaustion in critically ill patients. Accordingly, the immune system seems to play an important role in the prognosis and pathogenesis of the disease. Therefore, this study aims to review the evidence on the immune response dysregulation in COVID-19 infection and the potential role of immunoregulatory treatments such as immune checkpoint inhibitors, interferons, and CD200 inhibitors in altering disease prognosis, especially in critically ill patients.
کلیدواژه‌ها
Immunotherapy؛ COVID-19؛ Immune checkpoint inhibitors؛ T-lymphocytes
سایر فایل های مرتبط با مقاله
مراجع
  1. Ghebreyesus TA, Swaminathan S. Scientists are sprinting to outpace the novel coronavirus. Lancet. 2020;395:762-4. doi: 10.1016/S0140-6736(20)30420-7. PubMed PMID: 32105610; PubMed Central PMCID: PMCPMC7159275.
  2. Wei C, Friedman AJ. COVID-19 Pandemic: Are There Unique Cutaneous Manifestations in Patients Infected With SARS-CoV-2? J Drugs Dermatol. 2020;19:554-5. PubMed PMID: 32484624.
  3. Nagar K, Darji J. Perception of Nursing College Students Towards Online Teaching in COVID-19 Pandemic, A Cross Sectional Study. Asian Journal of Advances in Medical Science. 2021:190-4.
  4. O’Keefe JB, Tong EJ, O’Keefe GD, Tong DC. Description of symptom course in a telemedicine monitoring clinic for acute symptomatic COVID-19: a retrospective cohort study. BMJ Open. 2021;11:e044154. doi: 10.1136/bmjopen-2020-044154. PubMed PMID: 33674374; PubMed Central PMCID: PMCPMC7938467.
  5. Lu H, Stratton CW, Tang YW. Outbreak of pneumonia of unknown etiology in Wuhan, China: The mystery and the miracle. J Med Virol. 2020;92:401-2. doi: 10.1002/jmv.25678. PubMed PMID: 31950516; PubMed Central PMCID: PMCPMC7166628.
  6. Montero F, Martinez-Barrio J, Serrano-Benavente B, Gonzalez T, Rivera J, Molina Collada J, et al. Coronavirus disease 2019 (COVID-19) in autoimmune and inflammatory conditions: clinical characteristics of poor outcomes. Rheumatol Int. 2020;40:1593-8. doi: 10.1007/s00296-020-04676-4. PubMed PMID: 32794113; PubMed Central PMCID: PMCPMC7425254.
  7. Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J Autoimmun. 2020;109:102433. doi: 10.1016/j.jaut.2020.102433. PubMed PMID: 32113704; PubMed Central PMCID: PMCPMC7127067.
  8. Al-Quteimat OM, Amer AM. The Impact of the COVID-19 Pandemic on Cancer Patients. Am J Clin Oncol. 2020;43:452-5. doi: 10.1097/COC.0000000000000712. PubMed PMID: 32304435; PubMed Central PMCID: PMCPMC7188063.
  9. Dai M, Liu D, Liu M, Zhou F, Li G, Chen Z, et al. Patients with Cancer Appear More Vulnerable to SARS-CoV-2: A Multicenter Study during the COVID-19 Outbreak. Cancer Discov. 2020;10:783-91. doi: 10.1158/2159-8290.CD-20-0422. PubMed PMID: 32345594; PubMed Central PMCID: PMCPMC7309152.
  10. Fedele P, Sanna V, Fancellu A, Marino A, Calvani N, Cinieri S. De-escalating cancer treatments during COVID 19 pandemic: Is metronomic chemotherapy a reasonable option? Crit Rev Oncol Hematol. 2021;157:103148. doi: 10.1016/j.critrevonc.2020.103148. PubMed PMID: 33254036; PubMed Central PMCID: PMCPMC7672334.
  11. Bai Y, Yao L, Wei T, Tian F, Jin DY, Chen L, et al. Presumed Asymptomatic Carrier Transmission of COVID-19. JAMA. 2020;323:1406-7. doi: 10.1001/jama.2020.2565. PubMed PMID: 32083643; PubMed Central PMCID: PMCPMC7042844.
  12. Bersanelli M. Controversies about COVID-19 and anticancer treatment with immune checkpoint inhibitors. Immunotherapy. 2020;12:269-73. doi: 10.2217/imt-2020-0067. PubMed PMID: 32212881; PubMed Central PMCID: PMCPMC7117596.
  13. Darvin P, Toor SM, Sasidharan Nair V, Elkord E. Immune checkpoint inhibitors: recent progress and potential biomarkers. Exp Mol Med. 2018;50:1-11. doi: 10.1038/s12276-018-0191-1. PubMed PMID: 30546008; PubMed Central PMCID: PMCPMC6292890.
  14. Hargadon KM, Johnson CE, Williams CJ. Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors. Int Immunopharmacol. 2018;62:29-39. doi: 10.1016/j.intimp.2018.06.001. PubMed PMID: 29990692.
  15. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366:2443-54. doi: 10.1056/NEJMoa1200690. PubMed PMID: 22658127; PubMed Central PMCID: PMCPMC3544539.
  16. Bersanelli M, Buti S. From targeting the tumor to targeting the immune system: Transversal challenges in oncology with the inhibition of the PD-1/PD-L1 axis. World J Clin Oncol. 2017;8:37-53. doi: 10.5306/wjco.v8.i1.37. PubMed PMID: 28246584; PubMed Central PMCID: PMCPMC5309713.
  17. Paces J, Strizova Z, Smrz D, Cerny J. COVID-19 and the immune system. Physiol Res. 2020;69:379-88. doi: 10.33549/physiolres.934492. PubMed PMID: 32469225; PubMed Central PMCID: PMCPMC8648321.
  18. Kasuga Y, Zhu B, Jang KJ, Yoo JS. Innate immune sensing of coronavirus and viral evasion strategies. Exp Mol Med. 2021;53:723-36. doi: 10.1038/s12276-021-00602-1. PubMed PMID: 33953325; PubMed Central PMCID: PMCPMC8099713.
  19. Du F, Liu B, Zhang S. COVID-19: the role of excessive cytokine release and potential ACE2 down-regulation in promoting hypercoagulable state associated with severe illness. J Thromb Thrombolysis. 2021;51:313-29. doi: 10.1007/s11239-020-02224-2. PubMed PMID: 32676883; PubMed Central PMCID: PMCPMC7365308.
  20. Olejnik J, Hume AJ, Muhlberger E. Toll-like receptor 4 in acute viral infection: Too much of a good thing. PLoS Pathog. 2018;14:e1007390. doi: 10.1371/journal.ppat.1007390. PubMed PMID: 30571771; PubMed Central PMCID: PMCPMC6301565.
  21. Vaine CA, Soberman RJ. The CD200-CD200R1 inhibitory signaling pathway: immune regulation and host-pathogen interactions. Adv Immunol. 2014;121:191-211. doi: 10.1016/B978-0-12-800100-4.00005-2. PubMed PMID: 24388216; PubMed Central PMCID: PMCPMC4617684.
  22. Long EO. Regulation of immune responses through inhibitory receptors. Annu Rev Immunol. 1999;17:875-904. doi: 10.1146/annurev.immunol.17.1.875. PubMed PMID: 10358776.
  23. Timmerman LM, de Graaf JF, Satravelas N, Kesmir C, Meyaard L, van der Vlist M. Identification of a novel conserved signaling motif in CD200 receptor required for its inhibitory function. PLoS One. 2021;16:e0244770. doi: 10.1371/journal.pone.0244770. PubMed PMID: 33780466; PubMed Central PMCID: PMCPMC8007030.
  24. Gorczynski RM, Lee L, Boudakov I. Augmented induction of CD4+CD25+ Treg using monoclonal antibodies to CD200R. Transplantation. 2005;79:488-91. PubMed PMID: 15729177.
  25. Ngwa C, Liu F. CD200-CD200R signaling and diseases: a potential therapeutic target? Int J Physiol Pathophysiol Pharmacol. 2019;11:297-309. PubMed PMID: 31993106; PubMed Central PMCID: PMCPMC6971504.
  26. Chen Z, Marsden PA, Gorczynski RM. Role of a distal enhancer in the transcriptional responsiveness of the human CD200 gene to interferon-gamma and tumor necrosis factor-alpha. Mol Immunol. 2009;46:1951-63. doi: 10.1016/j.molimm.2009.03.015. PubMed PMID: 19386363.
  27. Mukhopadhyay S, Pluddemann A, Hoe JC, Williams KJ, Varin A, Makepeace K, et al. Immune inhibitory ligand CD200 induction by TLRs and NLRs limits macrophage activation to protect the host from meningococcal septicemia. Cell Host Microbe. 2010;8:236-47. doi: 10.1016/j.chom.2010.08.005. PubMed PMID: 20833375.
  28. Hall MW, Joshi I, Leal L, Ooi EE. Immune Immunomodulation in Coronavirus Disease 2019 (COVID-19): Strategic Considerations for Personalized Therapeutic Intervention. Clin Infect Dis. 2022;74:144-8. doi: 10.1093/cid/ciaa904. PubMed PMID: 32604407; PubMed Central PMCID: PMCPMC7337699.
  29. Zhong J, Tang J, Ye C, Dong L. The immunology of COVID-19: is immune modulation an option for treatment? Lancet Rheumatol. 2020;2:e428-e36. doi: 10.1016/S2665-9913(20)30120-X. PubMed PMID: 32835246; PubMed Central PMCID: PMCPMC7239618.
  30. Giamarellos-Bourboulis EJ, Netea MG, Rovina N, Akinosoglou K, Antoniadou A, Antonakos N, et al. Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure. Cell Host Microbe. 2020;27:992-1000. doi: 10.1016/j.chom.2020.04.009. PubMed PMID: 32320677; PubMed Central PMCID: PMCPMC7172841.
  31. Yao C, Bora SA, Parimon T, Zaman T, Friedman OA, Palatinus JA, et al. Cell-Type-Specific Immune Dysregulation in Severely Ill COVID-19 Patients. Cell Rep. 2021;34:108590. doi: 10.1016/j.celrep.2020.108590. PubMed PMID: 33357411; PubMed Central PMCID: PMCPMC7744012.
  32. Qin C, Ziwei MPLZM, Tao SYMY, Ke PCXMP, Shang MMPK. Dysregulation of immune response in patients with COVID-19 in Wuhan, China. Oxford Academic: Clinical Infectious Diseases. 2020.
  33. Diao B, Wang C, Tan Y, Chen X, Liu Y, Ning L, et al. Reduction and Functional Exhaustion of T Cells in Patients With Coronavirus Disease 2019 (COVID-19). Front Immunol. 2020;11:827. doi: 10.3389/fimmu.2020.00827. PubMed PMID: 32425950; PubMed Central PMCID: PMCPMC7205903.
  34. Sallard E, Lescure FX, Yazdanpanah Y, Mentre F, Peiffer-Smadja N. Type 1 interferons as a potential treatment against COVID-19. Antiviral Res. 2020;178:104791. doi: 10.1016/j.antiviral.2020.104791. PubMed PMID: 32275914; PubMed Central PMCID: PMCPMC7138382.
  35. Zhou Q, Chen V, Shannon CP, Wei XS, Xiang X, Wang X, et al. Interferon-alpha2b Treatment for COVID-19. Front Immunol. 2020;11:1061. doi: 10.3389/fimmu.2020.01061. PubMed PMID: 32574262; PubMed Central PMCID: PMCPMC7242746.
  36. Meng Z, Wang T, Chen L, Chen X, Li L, Qin X, et al. An experimental trial of recombinant human interferon alpha nasal drops to prevent COVID-19 in medical staff in an epidemic area. MedRxiv. 2020. doi: 10.1101/2020.04.11.20061473.
  37. El Bairi K, Trapani D, Petrillo A, Le Page C, Zbakh H, Daniele B, et al. Repurposing anticancer drugs for the management of COVID-19. Eur J Cancer. 2020;141:40-61. doi: 10.1016/j.ejca.2020.09.014. PubMed PMID: 33125946; PubMed Central PMCID: PMCPMC7508523.
  38. Kotwica-Mojzych K, Jodlowska-Jedrych B, Mojzych M. CD200:CD200R Interactions and Their Importance in Immunoregulation. Int J Mol Sci. 2021;22. doi: 10.3390/ijms22041602. PubMed PMID: 33562512; PubMed Central PMCID: PMCPMC7915401.
  39. Karnam G, Rygiel TP, Raaben M, Grinwis GC, Coenjaerts FE, Ressing ME, et al. CD200 receptor controls sex-specific TLR7 responses to viral infection. PLoS Pathog. 2012;8:e1002710. doi: 10.1371/journal.ppat.1002710. PubMed PMID: 22615569; PubMed Central PMCID: PMCPMC3355091.
  40. Kovacsovics T, Raetz E. Personalizing Therapy: The Beat AML Trial. The Hematologist. 2017;14. doi: 10.1182/hem.V14.2.7134.
  41. Hubel P, Urban C, Bergant V, Schneider WM, Knauer B, Stukalov A, et al. A protein-interaction network of interferon-stimulated genes extends the innate immune system landscape. Nat Immunol. 2019;20:493-502. doi: 10.1038/s41590-019-0323-3. PubMed PMID: 30833792.
  42. Friedman RM. Antiviral activity of interferons. Bacteriol Rev. 1977;41:543-67. doi: 10.1128/br.41.3.543-567.1977. PubMed PMID: 199154; PubMed Central PMCID: PMCPMC414016.
  43. Kaur A, Fang C-M. An overview of the human immune system and the role of interferon regulatory factors (IRFs). Progress In Microbes & Molecular Biology. 2020;3. doi: 10.36877/pmmb.a0000129.
  44. Lim YX, Ng YL, Tam JP, Liu DX. Human Coronaviruses: A Review of Virus-Host Interactions. Diseases. 2016;4. doi: 10.3390/diseases4030026. PubMed PMID: 28933406; PubMed Central PMCID: PMCPMC5456285.
  45. Blanco-Melo D, Nilsson-Payant BE, Liu WC, Uhl S, Hoagland D, Moller R, et al. Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19. Cell. 2020;181:1036-45. doi: 10.1016/j.cell.2020.04.026. PubMed PMID: 32416070; PubMed Central PMCID: PMCPMC7227586.
  46. Park A, Iwasaki A. Type I and Type III Interferons - Induction, Signaling, Evasion, and Application to Combat COVID-19. Cell Host Microbe. 2020;27:870-8. doi: 10.1016/j.chom.2020.05.008. PubMed PMID: 32464097; PubMed Central PMCID: PMCPMC7255347.
  47. Channappanavar R, Fehr AR, Zheng J, Wohlford-Lenane C, Abrahante JE, Mack M, et al. IFN-I response timing relative to virus replication determines MERS coronavirus infection outcomes. J Clin Invest. 2019;129:3625-39. doi: 10.1172/JCI126363. PubMed PMID: 31355779; PubMed Central PMCID: PMCPMC6715373.
  48. Wei L, Ming S, Zou B, Wu Y, Hong Z, Li Z, et al. Viral invasion and type i interferon response characterize the immunophenotypes during COVID-19 infection. 2020. doi: 10.2139/ssrn.3564998.
  49. Stockman LJ, Bellamy R, Garner P. SARS: systematic review of treatment effects. PLoS Med. 2006;3:e343. doi: 10.1371/journal.pmed.0030343. PubMed PMID: 16968120; PubMed Central PMCID: PMCPMC1564166.
  50. Meng Z, Wang T, Chen L, Chen X, Li L, Qin X, et al. The Effect of Recombinant Human Interferon Alpha Nasal Drops to Prevent COVID-19 Pneumonia for Medical Staff in an Epidemic Area. Curr Top Med Chem. 2021;21:920-7. doi: 10.2174/1568026621666210429083050. PubMed PMID: 33970846.
  51. Akinleye A, Rasool Z. Immune checkpoint inhibitors of PD-L1 as cancer therapeutics. J Hematol Oncol. 2019;12:92. doi: 10.1186/s13045-019-0779-5. PubMed PMID: 31488176; PubMed Central PMCID: PMCPMC6729004.
  52. Wilky BA. Immune checkpoint inhibitors: The linchpins of modern immunotherapy. Immunol Rev. 2019;290:6-23. doi: 10.1111/imr.12766. PubMed PMID: 31355494.
  53. Atkins S, He F. Chemotherapy and Beyond: Infections in the Era of Old and New Treatments for Hematologic Malignancies. Infect Dis Clin North Am. 2019;33:289-309. doi: 10.1016/j.idc.2019.01.001. PubMed PMID: 30935703.
  54. Shah NJ, Al-Shbool G, Blackburn M, Cook M, Belouali A, Liu SV, et al. Safety and efficacy of immune checkpoint inhibitors (ICIs) in cancer patients with HIV, hepatitis B, or hepatitis C viral infection. J Immunother Cancer. 2019;7:353. doi: 10.1186/s40425-019-0771-1. PubMed PMID: 31847881; PubMed Central PMCID: PMCPMC6918622.
  55. Maio M, Hamid O, Larkin J, Covre A, Altomonte M, Calabro L, et al. Immune Checkpoint Inhibitors for Cancer Therapy in the COVID-19 Era. Clin Cancer Res. 2020;26:4201-5. doi: 10.1158/1078-0432.CCR-20-1657. PubMed PMID: 32540850.
  56. Saeidi A, Zandi K, Cheok YY, Saeidi H, Wong WF, Lee CYQ, et al. T-Cell Exhaustion in Chronic Infections: Reversing the State of Exhaustion and Reinvigorating Optimal Protective Immune Responses. Front Immunol. 2018;9:2569. doi: 10.3389/fimmu.2018.02569. PubMed PMID: 30473697; PubMed Central PMCID: PMCPMC6237934.
  57. Blank CU, Haining WN, Held W, Hogan PG, Kallies A, Lugli E, et al. Defining ‘T cell exhaustion’. Nat Rev Immunol. 2019;19:665-74. doi: 10.1038/s41577-019-0221-9. PubMed PMID: 31570879; PubMed Central PMCID: PMCPMC7286441.
  58. Kahan SM, Wherry EJ, Zajac AJ. T cell exhaustion during persistent viral infections. Virology. 2015;479-480:180-93. doi: 10.1016/j.virol.2014.12.033. PubMed PMID: 25620767; PubMed Central PMCID: PMCPMC4424083.
  59. Bellesi S, Metafuni E, Hohaus S, Maiolo E, Marchionni F, D’Innocenzo S, et al. Increased CD95 (Fas) and PD-1 expression in peripheral blood T lymphocytes in COVID-19 patients. Br J Haematol. 2020;191:207-11. doi: 10.1111/bjh.17034. PubMed PMID: 32679621; PubMed Central PMCID: PMCPMC7405050.
  60. Fenwick C, Joo V, Jacquier P, Noto A, Banga R, Perreau M, et al. T-cell exhaustion in HIV infection. Immunol Rev. 2019;292:149-63. doi: 10.1111/imr.12823. PubMed PMID: 31883174; PubMed Central PMCID: PMCPMC7003858.
  61. Tanaka R, Okiyama N, Okune M, Ishitsuka Y, Watanabe R, Furuta J, et al. Serum level of interleukin-6 is increased in nivolumab-associated psoriasiform dermatitis and tumor necrosis factor-alpha is a biomarker of nivolumab recativity. J Dermatol Sci. 2017;86:71-3. doi: 10.1016/j.jdermsci.2016.12.019. PubMed PMID: 28069323.
  62. Raschi E, Gatti M, Gelsomino F, Ardizzoni A, Poluzzi E, De Ponti F. Lessons to be Learnt from Real-World Studies on Immune-Related Adverse Events with Checkpoint Inhibitors: A Clinical Perspective from Pharmacovigilance. Target Oncol. 2020;15:449-66. doi: 10.1007/s11523-020-00738-6. PubMed PMID: 32725437; PubMed Central PMCID: PMCPMC7434791.
  63. Nobashi TW, Nishimoto Y, Kawata Y, Yutani H, Nakamura M, Tsuji Y, et al. Clinical and radiological features of immune checkpoint inhibitor-related pneumonitis in lung cancer and non-lung cancers. Br J Radiol. 2020;93:20200409. doi: 10.1259/bjr.20200409. PubMed PMID: 32783627; PubMed Central PMCID: PMCPMC8519648.
آمار
تعداد مشاهده مقاله: 3,330
تعداد دریافت فایل اصل مقاله: 2,112


سامانه مدیریت نشریات علمی. قدرت گرفته از سیناوب